GlaxoSmithKline study shows benefits of Relvar Ellipta for asthma

GlaxoSmithKline has announced the findings of a new study that demonstrates the significant benefits associated with its asthma drug Relvar Ellipta.

Data from the Salford Lung Study (SLS), carried out among 4,233 patients treated by their GP in everyday clinical practice, showed that significantly more asthma patients initiated on treatment with Relvar Ellipta achieved an improvement in asthma control compared with usual care treatment, including inhaled corticosteroids and long-acting beta agonists.

It meant the primary endpoint of the study was achieved, with Relvar Ellipta patients experiencing twice the odds of achieving an improvement in asthma control compared with those continuing usual care.

This marks the second SLS study with Relvar Ellipta to deliver positive results, the first targeting patients with chronic obstructive pulmonary disease.

Eric Dube, senior vice-president and head of GlaxoSmithKline's global respiratory franchise, said: "This study has been a tremendous partnership effort between healthcare professionals, patients, academics and GlaxoSmithKline, and we would like to thank everyone who has helped to make this unique study possible."

The study involved the participation of North West e-Health, the University of Manchester, Salford Royal NHS Foundation Trust, the University Hospital of South Manchester and NHS Salford, as well as GPs and community pharmacists in Salford, Trafford and South Manchester.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.